Volume Alert - SLXP 98.62 Salix Pharmaceuticals $SLXP Hit a high today of 100.29 Closing the day 10:30 at 98.62 +1.63 +1.68% With a day low of 97.98 and a total volume of 1,061,125.
SLXP Recent Posts: http://investorshangout.com/Salix-Pharmaceuti...LXP-55453/
SLXP Salix Pharmaceuticals Recent Headline News
Upgrade Alert for Salix Pharmaceuticals (SLXP)
Comtex SmarTrend(R) - Fri Nov 14, 7:05AM CST
Salix Pharmaceuticals (NASDAQ:SLXP) was upgraded from Neutral to Buy at UBS today. The stock closed yesterday at $96.99 on volume of 3.9 million shares, above average daily volume of 2.9 million. There is potential upside of 73.8% for shares of Salix Pharmaceuticals based on a current price of $96.99 and an average consensus analyst price target of $168.59. Salix Pharmaceuticals shares should first meet resistance at the 200-day moving average (MA) of $124.39 and find additional resistance at the 50-day MA of $142.49.
SLXP: 100.20 (+3.21)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Salix Pharmaceuticals, Ltd. to Contact Brower Piven Before the January 6, 2015 Lead Plaintiff Deadline in Class Action Lawsuit -- SLXP
GlobeNewswire - Thu Nov 13, 7:52PM CST
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Salix Pharmaceuticals, Ltd. ("Salix" or the "Company"
(Nasdaq:SLXP) securities during the period between November 7, 2013 and November 6, 2014, inclusive (the "Class Period" . Investors who wish to become proactively involved in the litigation have until January 6, 2015 to seek appointment as lead plaintiff.
SLXP: 100.20 (+3.21)
Lieff Cabraser Announces Class Action Litigation Against Salix Pharmaceuticals, Inc. - SLXP
Business Wire - Thu Nov 13, 2:05PM CST
The law firm of Lieff Cabraser Heimann & Bernstein, LLP announces that class action litigation has been brought on behalf of those who purchased or otherwise acquired the securities of Salix Pharmaceuticals, Inc. ("Salix" or the "Company" (NasdaqGS: SLXP) between November 8, 2013 and November 6, 2014, inclusive (the "Class Period" .
SLXP: 100.20 (+3.21)
Robbins Arroyo LLP: Salix Pharmaceuticals, Ltd. (SLXP) Misled Shareholders According to a Recently Filed Class Action
GlobeNewswire - Wed Nov 12, 6:05PM CST
Shareholder rights law firm Robbins Arroyo LLP announces that an investor of Salix Pharmaceuticals, Ltd. (Nasdaq:SLXP) has filed a federal securities fraud class action complaint in the U.S. District Court for the Southern District of New York. The complaint alleges that the company and certain of its officers and directors violated the Securities Exchange Act of 1934 between November 8, 2013 and November 6, 2014. Salix is a pharmaceutical company that focuses on treatments for digestive system diseases and disorders.
SLXP: 100.20 (+3.21)
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Salix Pharmaceuticals Ltd and Certain Officers -- SLXP
GlobeNewswire - Wed Nov 12, 5:21PM CST
Pomerantz LLP has filed a class action lawsuit against Salix Pharmaceuticals Ltd ("Salix" or the "Company" (Nasdaq:SLXP) and certain of its officers. The class action, filed in United States District Court, Eastern District of North Carolina, Western Division, and docketed under 14-cv-00804, is on behalf of a class consisting of all persons or entities who purchased Salix securities between August 7, 2014 and November 6, 2014, inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act" .
SLXP: 100.20 (+3.21)
SHAREHOLDER ALERT: Investors of Salix Pharmaceuticals, Ltd. with Losses of $250,000 or More Are Encouraged to Contact Glancy Binkow & Goldberg LLP
Business Wire - Wed Nov 12, 11:32AM CST
Glancy Binkow & Goldberg LLP announces that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of a class (the "Class" comprising purchasers of the securities of Salix Pharmaceuticals, Ltd. ("Salix" or the "Company" (NASDAQ:SLXP) between November 7, 2013 and November 6, 2014, inclusive (the "Class Period" . Investors who have losses of $250,000 or more are encouraged to contact the firm for more information.
SLXP: 100.20 (+3.21)
INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Salix Pharmaceuticals Inc. (SLXP) To Contact The Firm
PR Newswire - Tue Nov 11, 4:23PM CST
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Salix Pharmaceuticals Inc. ("Salix" or the "Company" (NASDAQ: SLXP) of the January 6, 2015 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against Salix and certain executives.
SLXP: 100.20 (+3.21)
Lifshitz & Miller Law Firm Announces Investigation of Barrett Business Services, Inc., Bio-Rad Laboratories, Inc., Pingtan Marine Enterprise Ltd., Rayonier Inc. and Salix Pharmaceuticals, Ltd.
PR Newswire - Tue Nov 11, 11:10AM CST
Barrett Business Services, Inc.
RYN: 26.01 (-0.12), BIO: 111.42 (-0.12), BBSI: 22.76 (+0.46), SLXP: 100.20 (+3.21), PME: 1.33 (unch)
Actavis Says 'Let's Make A Deal'
Bill Gunderson - Seeking Alpha - Tue Nov 11, 8:42AM CST
I wrote about generic and specialty drug company Actavis plc (NYSE: ACT ) a while back detailing the rumored love triangle between them, Allergan (NYSE: AGN ), Valeant Pharmaceuticals (NYSE: VRX ), and Salix Pharmaceuticals (NASDAQ: SLXP ). On...
DRTX: 23.81 (+0.06), AGN: 198.23 (+2.02), ACT: 244.31 (+2.68), VRX: 134.53 (+2.63), MDT: 69.11 (-0.27), SLXP: 100.20 (+3.21), SNY: 46.59 (+0.06)
Pharma Equities Technical Data - Salix Pharma, AstraZeneca, Novartis, Impax Laboratories, and Novo Nordisk
PR Newswire - Tue Nov 11, 8:05AM CST
Investor-Edge has initiated coverage on the following equities: Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), AstraZeneca PLC (NYSE: AZN), Novartis AG (NYSE: NVS), Impax Laboratories Inc. (NASDAQ: IPXL), and Novo Nordisk A/S (NYSE: NVO). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Monday, November 10, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,613.74, up 0.23% and the NASDAQ Composite closed at 4,651.62, up 0.41%. The S&P 500 finished the session 0.31% higher at 2,038.26. During the trading session, eight out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 783.00, up 1.00%, with the index gaining 11.86% in the previous three months. Register for your complimentary reports on these five stocks at:
IPXL: 28.83 (-0.23), NVO: 43.97 (-0.05), AZN: 72.78 (-1.75), SLXP: 100.20 (+3.21), NVS: 93.77 (-0.61)
Hagens Berman Alerts Investors of Lead Plaintiff Deadline in Class Action Lawsuit Filed Against Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP)
GlobeNewswire - Tue Nov 11, 7:38AM CST
Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm, alerts investors that a class action lawsuit has been filed against Salix Pharmaceuticals, Ltd. (Nasdaq:SLXP) ("Salix" or "the Company). The suit is pending in U.S. District Court for the Southern District of New York, and investors have until January 6, 2015 to move for lead plaintiff.
SLXP: 100.20 (+3.21)
Salix Pharmaceuticals: What Scares Me Most About Its High Inventory & Stock Collapse
Brian Nichols - at Seeking Alpha - Tue Nov 11, 6:50AM CST
SLXP: 100.20 (+3.21)
SALIX SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Salix Pharmaceuticals Ltd. - SLXP
GlobeNewswire - Mon Nov 10, 9:00PM CST
Kahn Swick & Foti, LLC ("KSF" and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until January 6, 2015 to file lead plaintiff applications in a securities class action lawsuit against Salix Pharmaceuticals Ltd. (Nasdaq:SLXP) if they purchased the Company's securities between November 8, 2013 and November 6, 2014, inclusive (the "Class Period" . This action is pending in the United States District Court for the Southern District of New York.
SLXP: 100.20 (+3.21)
Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Salix Pharmaceuticals, Ltd.
Business Wire - Mon Nov 10, 3:28PM CST
Rigrodsky & Long, P.A.:
SLXP: 100.20 (+3.21)
SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Salix Pharmaceuticals, Ltd. and Its Board of Directors and a Lead Plaintiff Deadline of January 6, 2015 -- SLXP
GlobeNewswire - Mon Nov 10, 3:11PM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Salix Pharmaceuticals, Ltd. ("Salix" or the "Company" (Nasdaq:SLXP) securities between November 8, 2013 and November 6, 2014.
SLXP: 100.20 (+3.21)
Salix Crashes on Inventory Issues, Lowered Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Nov 10, 1:56PM CST
Salix's (SLXP) wholesale inventory levels for its products were much higher than previously announced.
AGN: 198.23 (+2.02), VRX: 134.53 (+2.63), AUXL: 32.25 (-0.10), SLXP: 100.20 (+3.21)
Wolf Popper LLP Announces Investigation on Behalf of Investors in Salix Pharmaceuticals Ltd.
PR Newswire - Mon Nov 10, 11:09AM CST
Wolf Popper LLP is investigating potential claims on behalf of investors in Salix Pharmaceuticals Ltd. ("Salix" common stock (NASDAQ: SLXP) during the period May 10, 2013 through November 6, 2014, concerning possible violations of federal securities laws. Such investors are advised to contact Fei-Lu Qian at 877.370.7703 or fqian@wolfpopper.com.
SLXP: 100.20 (+3.21)
Morgan & Morgan Announces That a Class Action Lawsuit Has Been Filed Against Salix Pharmaceuticals Ltd. -- SLXP
GlobeNewswire - Mon Nov 10, 10:40AM CST
Morgan & Morgan announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Salix Pharmaceuticals Ltd. ("Salix" or the "Company" (Nasdaq:SLXP) securities between November 8, 2013 and November 6, 2014, inclusive (the "Class Period" .
SLXP: 100.20 (+3.21)
Biotech Weekly: When Mid Caps Are Priced Nearly For Perfection
Daniel Ward - at Seeking Alpha - Mon Nov 10, 9:28AM CST
XBI: 167.53 (-3.81), SLXP: 100.20 (+3.21), ICPT: 161.00 (+2.14), IBB: 287.53 (-6.36), AGIO: 83.57 (-2.92)
Trade-Ideas: Salix Pharmaceuticals (SLXP) Is Today's "Dead Cat Bounce" Stock
at The Street - Mon Nov 10, 8:51AM CST
Trade-Ideas LLC identified Salix Pharmaceuticals (SLXP) as a "dead cat bounce" (down big yesterday but up big today) candidate
SLXP: 100.20 (+3.21)
SLXP Recent Posts: http://investorshangout.com/Salix-Pharmaceuti...LXP-55453/
SLXP Salix Pharmaceuticals Recent Headline News
Upgrade Alert for Salix Pharmaceuticals (SLXP)
Comtex SmarTrend(R) - Fri Nov 14, 7:05AM CST
Salix Pharmaceuticals (NASDAQ:SLXP) was upgraded from Neutral to Buy at UBS today. The stock closed yesterday at $96.99 on volume of 3.9 million shares, above average daily volume of 2.9 million. There is potential upside of 73.8% for shares of Salix Pharmaceuticals based on a current price of $96.99 and an average consensus analyst price target of $168.59. Salix Pharmaceuticals shares should first meet resistance at the 200-day moving average (MA) of $124.39 and find additional resistance at the 50-day MA of $142.49.
SLXP: 100.20 (+3.21)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Salix Pharmaceuticals, Ltd. to Contact Brower Piven Before the January 6, 2015 Lead Plaintiff Deadline in Class Action Lawsuit -- SLXP
GlobeNewswire - Thu Nov 13, 7:52PM CST
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Salix Pharmaceuticals, Ltd. ("Salix" or the "Company"
(Nasdaq:SLXP) securities during the period between November 7, 2013 and November 6, 2014, inclusive (the "Class Period" . Investors who wish to become proactively involved in the litigation have until January 6, 2015 to seek appointment as lead plaintiff. SLXP: 100.20 (+3.21)
Lieff Cabraser Announces Class Action Litigation Against Salix Pharmaceuticals, Inc. - SLXP
Business Wire - Thu Nov 13, 2:05PM CST
The law firm of Lieff Cabraser Heimann & Bernstein, LLP announces that class action litigation has been brought on behalf of those who purchased or otherwise acquired the securities of Salix Pharmaceuticals, Inc. ("Salix" or the "Company"
(NasdaqGS: SLXP) between November 8, 2013 and November 6, 2014, inclusive (the "Class Period" . SLXP: 100.20 (+3.21)
Robbins Arroyo LLP: Salix Pharmaceuticals, Ltd. (SLXP) Misled Shareholders According to a Recently Filed Class Action
GlobeNewswire - Wed Nov 12, 6:05PM CST
Shareholder rights law firm Robbins Arroyo LLP announces that an investor of Salix Pharmaceuticals, Ltd. (Nasdaq:SLXP) has filed a federal securities fraud class action complaint in the U.S. District Court for the Southern District of New York. The complaint alleges that the company and certain of its officers and directors violated the Securities Exchange Act of 1934 between November 8, 2013 and November 6, 2014. Salix is a pharmaceutical company that focuses on treatments for digestive system diseases and disorders.
SLXP: 100.20 (+3.21)
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Salix Pharmaceuticals Ltd and Certain Officers -- SLXP
GlobeNewswire - Wed Nov 12, 5:21PM CST
Pomerantz LLP has filed a class action lawsuit against Salix Pharmaceuticals Ltd ("Salix" or the "Company"
(Nasdaq:SLXP) and certain of its officers. The class action, filed in United States District Court, Eastern District of North Carolina, Western Division, and docketed under 14-cv-00804, is on behalf of a class consisting of all persons or entities who purchased Salix securities between August 7, 2014 and November 6, 2014, inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act" . SLXP: 100.20 (+3.21)
SHAREHOLDER ALERT: Investors of Salix Pharmaceuticals, Ltd. with Losses of $250,000 or More Are Encouraged to Contact Glancy Binkow & Goldberg LLP
Business Wire - Wed Nov 12, 11:32AM CST
Glancy Binkow & Goldberg LLP announces that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of a class (the "Class"
comprising purchasers of the securities of Salix Pharmaceuticals, Ltd. ("Salix" or the "Company" (NASDAQ:SLXP) between November 7, 2013 and November 6, 2014, inclusive (the "Class Period" . Investors who have losses of $250,000 or more are encouraged to contact the firm for more information. SLXP: 100.20 (+3.21)
INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Salix Pharmaceuticals Inc. (SLXP) To Contact The Firm
PR Newswire - Tue Nov 11, 4:23PM CST
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Salix Pharmaceuticals Inc. ("Salix" or the "Company"
(NASDAQ: SLXP) of the January 6, 2015 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against Salix and certain executives. SLXP: 100.20 (+3.21)
Lifshitz & Miller Law Firm Announces Investigation of Barrett Business Services, Inc., Bio-Rad Laboratories, Inc., Pingtan Marine Enterprise Ltd., Rayonier Inc. and Salix Pharmaceuticals, Ltd.
PR Newswire - Tue Nov 11, 11:10AM CST
Barrett Business Services, Inc.
RYN: 26.01 (-0.12), BIO: 111.42 (-0.12), BBSI: 22.76 (+0.46), SLXP: 100.20 (+3.21), PME: 1.33 (unch)
Actavis Says 'Let's Make A Deal'
Bill Gunderson - Seeking Alpha - Tue Nov 11, 8:42AM CST
I wrote about generic and specialty drug company Actavis plc (NYSE: ACT ) a while back detailing the rumored love triangle between them, Allergan (NYSE: AGN ), Valeant Pharmaceuticals (NYSE: VRX ), and Salix Pharmaceuticals (NASDAQ: SLXP ). On...
DRTX: 23.81 (+0.06), AGN: 198.23 (+2.02), ACT: 244.31 (+2.68), VRX: 134.53 (+2.63), MDT: 69.11 (-0.27), SLXP: 100.20 (+3.21), SNY: 46.59 (+0.06)
Pharma Equities Technical Data - Salix Pharma, AstraZeneca, Novartis, Impax Laboratories, and Novo Nordisk
PR Newswire - Tue Nov 11, 8:05AM CST
Investor-Edge has initiated coverage on the following equities: Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), AstraZeneca PLC (NYSE: AZN), Novartis AG (NYSE: NVS), Impax Laboratories Inc. (NASDAQ: IPXL), and Novo Nordisk A/S (NYSE: NVO). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Monday, November 10, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,613.74, up 0.23% and the NASDAQ Composite closed at 4,651.62, up 0.41%. The S&P 500 finished the session 0.31% higher at 2,038.26. During the trading session, eight out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 783.00, up 1.00%, with the index gaining 11.86% in the previous three months. Register for your complimentary reports on these five stocks at:
IPXL: 28.83 (-0.23), NVO: 43.97 (-0.05), AZN: 72.78 (-1.75), SLXP: 100.20 (+3.21), NVS: 93.77 (-0.61)
Hagens Berman Alerts Investors of Lead Plaintiff Deadline in Class Action Lawsuit Filed Against Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP)
GlobeNewswire - Tue Nov 11, 7:38AM CST
Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm, alerts investors that a class action lawsuit has been filed against Salix Pharmaceuticals, Ltd. (Nasdaq:SLXP) ("Salix" or "the Company). The suit is pending in U.S. District Court for the Southern District of New York, and investors have until January 6, 2015 to move for lead plaintiff.
SLXP: 100.20 (+3.21)
Salix Pharmaceuticals: What Scares Me Most About Its High Inventory & Stock Collapse
Brian Nichols - at Seeking Alpha - Tue Nov 11, 6:50AM CST
SLXP: 100.20 (+3.21)
SALIX SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Salix Pharmaceuticals Ltd. - SLXP
GlobeNewswire - Mon Nov 10, 9:00PM CST
Kahn Swick & Foti, LLC ("KSF"
and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until January 6, 2015 to file lead plaintiff applications in a securities class action lawsuit against Salix Pharmaceuticals Ltd. (Nasdaq:SLXP) if they purchased the Company's securities between November 8, 2013 and November 6, 2014, inclusive (the "Class Period" . This action is pending in the United States District Court for the Southern District of New York. SLXP: 100.20 (+3.21)
Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Salix Pharmaceuticals, Ltd.
Business Wire - Mon Nov 10, 3:28PM CST
Rigrodsky & Long, P.A.:
SLXP: 100.20 (+3.21)
SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Salix Pharmaceuticals, Ltd. and Its Board of Directors and a Lead Plaintiff Deadline of January 6, 2015 -- SLXP
GlobeNewswire - Mon Nov 10, 3:11PM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Salix Pharmaceuticals, Ltd. ("Salix" or the "Company"
(Nasdaq:SLXP) securities between November 8, 2013 and November 6, 2014. SLXP: 100.20 (+3.21)
Salix Crashes on Inventory Issues, Lowered Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Nov 10, 1:56PM CST
Salix's (SLXP) wholesale inventory levels for its products were much higher than previously announced.
AGN: 198.23 (+2.02), VRX: 134.53 (+2.63), AUXL: 32.25 (-0.10), SLXP: 100.20 (+3.21)
Wolf Popper LLP Announces Investigation on Behalf of Investors in Salix Pharmaceuticals Ltd.
PR Newswire - Mon Nov 10, 11:09AM CST
Wolf Popper LLP is investigating potential claims on behalf of investors in Salix Pharmaceuticals Ltd. ("Salix"
common stock (NASDAQ: SLXP) during the period May 10, 2013 through November 6, 2014, concerning possible violations of federal securities laws. Such investors are advised to contact Fei-Lu Qian at 877.370.7703 or fqian@wolfpopper.com. SLXP: 100.20 (+3.21)
Morgan & Morgan Announces That a Class Action Lawsuit Has Been Filed Against Salix Pharmaceuticals Ltd. -- SLXP
GlobeNewswire - Mon Nov 10, 10:40AM CST
Morgan & Morgan announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Salix Pharmaceuticals Ltd. ("Salix" or the "Company"
(Nasdaq:SLXP) securities between November 8, 2013 and November 6, 2014, inclusive (the "Class Period" . SLXP: 100.20 (+3.21)
Biotech Weekly: When Mid Caps Are Priced Nearly For Perfection
Daniel Ward - at Seeking Alpha - Mon Nov 10, 9:28AM CST
XBI: 167.53 (-3.81), SLXP: 100.20 (+3.21), ICPT: 161.00 (+2.14), IBB: 287.53 (-6.36), AGIO: 83.57 (-2.92)
Trade-Ideas: Salix Pharmaceuticals (SLXP) Is Today's "Dead Cat Bounce" Stock
at The Street - Mon Nov 10, 8:51AM CST
Trade-Ideas LLC identified Salix Pharmaceuticals (SLXP) as a "dead cat bounce" (down big yesterday but up big today) candidate
SLXP: 100.20 (+3.21)
